CIDP Clinical Trials 2023

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a disorder that targets the body's nerves. The neurological disorder shows different symptoms in patients, ranging from numbness to slow reflexes.

The cause of CIDP is still debated. However, experts have accounted for the effects of the disorder on the inflammation of nerves that results in myelin damage. Myelin forms a sheath around the nerves, nourishing and protecting them. Damaged myelin results in a slower impulse that can cause pain and numbness.

CIDP clinical trials are underway to assess the disorder's cause and treatment and evaluate the efficacy of already existing treatments.

Why are Clinical Trials Being Conducted for CIDP?

CIDP is a rare neurological disorder affecting five to seven of every 100,000 individuals. Globally, CIDP influences around three million people, with 40,000 Americans suffering from the condition. However, it is difficult to accurately estimate the number of CIDP patients as the disorder is challenging to diagnose and shows varying symptoms.

Due to a lack of understanding, there is no proper treatment for CIDP. Researchers have found ways to alleviate some of the symptoms and are continuously conducting CIDP clinical trials to assess their efficacy and find better treatment methods.

One of the main reasons for CIDP clinical trials is that the disorder closely resembles Guillain-Bare Syndrome (GBS). However, GBS is caused by an onset of illness and is short-lived. CIDP is a long-term condition, and the patient must suffer from symptoms for up to eight weeks to be considered affected by CIDP.

What are Some CIDP Clinical Trials for Treatment?

CIDP shows a broad spectrum of symptoms, and these variable presentations make it challenging to diagnose the disorder and assess clinical trial endpoints. Additionally, due to a lack of reliable biomarkers for CIDP, CIDP guidelines are lacking and debated. Despite the many challenges, researchers are conducting CIPD clinical trials to get one step closer to treatment.

Intravenous Immunoglobulins

Intravenous Immunoglobulin (IVIg) is one of the most common and well-established treatments for CIDP. However, the reason for the efficacy is still undergoing clinical trials, but most researchers believe that it targets B-cells and antibodies and cytokine secretion to mitigate inflammation and demyelination.

Several CIDP clinical trials and overviews have been conducted to assess the efficacy and pathology of IVIg in treating CIDP. One of the main CIDP clinical trials was a phase 3 trial of NPB-01 therapy in CIDP patients (NCT01824251).

Subcutaneous Immunoglobulin Therapy

IVIg therapy has shown many limitations and side effects in patients. Hence, clinical trials are now assessing the potentiality of Subcutaneous immunoglobulin (SCIg) as an alternative option for CIDP treatment. Several clinical trials have shown that patients who shift to SCIg treatment have improved their conditions.

One of the most extensive phase 3 subcutaneous immunoglobulin treatments in CIDO was the PATH trial (NCT01545076) which assessed patients that relapsed after IGIg treatments and were shifted to SCIg.

What are some CIDP Clinical Trials for Diagnosis

Many CIDP clinical trials aim to find biomarkers for better diagnosis and treatment. Some of the major clinical trials conducted include:

NCT03460951: A 2018 clinical trial to assess the feasibility of diffusion tensor imaging (DTI) in diagnosis CIDP.
NCT04249752: A 2020 clinical trial that evaluates and studies antibodies that target glycolipids and cell adhesion molecules where inflammation of nerves in GBS or CIDP occurred to identify them as potential biomarkers.
NCT026929796: A 2015 clinical study extended six years to asses intravenous immunoglobulin responders in CIDP as potential biomarkers.
NCT05004493: A 2021 study that aims to collect and study cryopreserve blood biospecimens such as plasma from patients suffering from CIDP and undergoing plasma exchange procedures.